Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis.

Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in #Oncology @JAMA_current @farmaciaclinico https://t.co/4NE33lP7N1

RT @frank_barreraf: Aumentar la sobrevida de los pacientes con cancer no se encuentra asociado con una buena calidad de vida https://t.co/…

RT @MikkaelSekeres: Wow - Progression-free Survival improvement without Quality of Life enhancement is a Pyrrhic victory, and meaningless t…

RT @frank_barreraf: Aumentar la sobrevida de los pacientes con cancer no se encuentra asociado con una buena calidad de vida https://t.co/…

RT @FuenteApolo: To ensure that patients are truly obtaining important benefit from cancer therapies, clinical trial investigators should m…

RT @FREELANCEROG: @FREELANCEROG está con los pacientes en su día a día. La calidad de vida importa. https://t.co/QIrFgQ7UwV

Sobrevida libre de enfermedad*

RT @conanso: Increasingly important to consider quality of life as an endpoint for cancer treatment. A systematic review of 38 studies in @…

RT @DrDeborahFisher: Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life HRQoL in Oncology. Systematic revi…

RT @FREELANCEROG: @FREELANCEROG está con los pacientes en su día a día. La calidad de vida importa. https://t.co/QIrFgQ7UwV

@FREELANCEROG está con los pacientes en su día a día. La calidad de vida importa.

To ensure that patients are truly obtaining important benefit from cancer therapies, clinical trial investigators should measure HRQoL directly and accurately, ensuring adequate duration and follow-up. 🙂✌️ https://t.co/vszKdDinfq @JAMAInternalMed

“To ensure that patients are truly obtaining important benefit from cancer therapies, clinical trial investigators should measure HRQoL directly and accurately, ensuring adequate duration and follow-up.”

RT @MikkaelSekeres: Wow - Progression-free Survival improvement without Quality of Life enhancement is a Pyrrhic victory, and meaningless t…

RT @JLSandoval: @AmeetSarpatwari mentions the recent lancet paper showing progression free survival is not a surrogate for patient quality…

RT @MikkaelSekeres: Wow - Progression-free Survival improvement without Quality of Life enhancement is a Pyrrhic victory, and meaningless t…

#quality of #life SO important for all #patients whatever the #disease and #treatment #Blooducation

RT @MikkaelSekeres: Wow - Progression-free Survival improvement without Quality of Life enhancement is a Pyrrhic victory, and meaningless t…

RT @MikkaelSekeres: Wow - Progression-free Survival improvement without Quality of Life enhancement is a Pyrrhic victory, and meaningless t…

‼️ (fail) Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/LZ6HOK6i9C

"We failed to find a significant association between PFS and HRQoL in cancer clinical trials." https://t.co/fyvtn9efTE #hpm #pallonc #hpeonc

RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…

RT @MikkaelSekeres: Wow - Progression-free Survival improvement without Quality of Life enhancement is a Pyrrhic victory, and meaningless t…

RT @frank_barreraf: Aumentar la sobrevida de los pacientes con cancer no se encuentra asociado con una buena calidad de vida https://t.co/…

RT @conanso: Increasingly important to consider quality of life as an endpoint for cancer treatment. A systematic review of 38 studies in @…

RT @K_Hawlik: Progression free survival often used in US to show benefit of oncology drugs @AmeetSarpatwari read here why it is not suffic…

RT @GI_RadOnc: Important study published in @JAMAInternalMed PFS is no surrogate for #HRQoL https://t.co/xuEQDJqYw2

Eagerly awaiting the full text of this paper - a major step in recasting the concept of survival to focus on patients rather than disease. Note: effective use of PROs to assess #HRQOL must include measures of physical function across the continuum of care

RT @conanso: Increasingly important to consider quality of life as an endpoint for cancer treatment. A systematic review of 38 studies in @…

Important study published in @JAMAInternalMed PFS is no surrogate for #HRQoL https://t.co/xuEQDJqYw2

RT @conanso: Increasingly important to consider quality of life as an endpoint for cancer treatment. A systematic review of 38 studies in @…

RT @MikkaelSekeres: Wow - Progression-free Survival improvement without Quality of Life enhancement is a Pyrrhic victory, and meaningless t…

@AmeetSarpatwari mentions the recent lancet paper showing progression free survival is not a surrogate for patient quality of life. #EHFG2018 #YFG2018 We need new ways to measure quality of life and incorporate them in clinical trials...PROs could be the

RT @FallowfieldLJ: Hardly a surprise, side effect profiles of novel therapies must be measured adequately with good PRO tools and ameliora…

Aumentar la sobrevida de los pacientes con cancer no se encuentra asociado con una buena calidad de vida https://t.co/OhlNgxjlFe

RT @K_Hawlik: Progression free survival often used in US to show benefit of oncology drugs @AmeetSarpatwari read here why it is not suffic…

Progression free survival often used in US to show benefit of oncology drugs @AmeetSarpatwari read here why it is not sufficient:https://t.co/Q4gmlLBGGb #EHFG2018 #GoodMedicines

RT @conanso: Increasingly important to consider quality of life as an endpoint for cancer treatment. A systematic review of 38 studies in @…

RT @K_Hawlik: Speaking about evidence:new Systematic review showing that Progression-Free Survival as a Surrogate Outcome for Health-Relate…

RT @TheWonkologist: If what we value is survival and quality of life, then why not measure survival and quality of life rather than PFS? In…

RT @conanso: Increasingly important to consider quality of life as an endpoint for cancer treatment. A systematic review of 38 studies in @…

RT @TheWonkologist: If what we value is survival and quality of life, then why not measure survival and quality of life rather than PFS? In…

Speaking about evidence:new Systematic review showing that Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology is not sufficient to show benefit #EHFG2018 #goodmedicines https://t.co/kTd2llJubm

Hardly a surprise, side effect profiles of novel therapies must be measured adequately with good PRO tools and ameliorative interventions implemented otherwise therapies represent an unacceptable waste of scarce resources providing patients with little

RT @rajshekharucms: Important meta-analysis questioning the dogma that PFS is a surrogate of #HRQoL; A key example is PALOMA-2 where >10 mo…

RT @MikkaelSekeres: Wow - Progression-free Survival improvement without Quality of Life enhancement is a Pyrrhic victory, and meaningless t…

RT @MikkaelSekeres: Wow - Progression-free Survival improvement without Quality of Life enhancement is a Pyrrhic victory, and meaningless t…

RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…

RT @MikkaelSekeres: Wow - Progression-free Survival improvement without Quality of Life enhancement is a Pyrrhic victory, and meaningless t…

Wow - Progression-free Survival improvement without Quality of Life enhancement is a Pyrrhic victory, and meaningless to patients. Why we should demand improvement in Overall Survival in clinical trials. https://t.co/lo6IhJ2fJv

RT @TheWonkologist: If what we value is survival and quality of life, then why not measure survival and quality of life rather than PFS? In…

RT @mlazqui: Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/TaWZisvkzA

Pas de lien entre survie sans progression du #cancer et qualité de vie : une méta-analyse le montre. Il faut donc évaluer ce dernier point à part avec les outils corrects. On le subodorait 😌 https://t.co/DVlFaZilp7

RT @mlazqui: Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/TaWZisvkzA

RT @irodriguezpenin: Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/KMfoO70f0G

RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…

RT @DrAndrewLoblaw: Ian Tannock Prof Emeritus and GU God just gave rounds @Sunnybrook arguing exactly the same point. RCTs should have OS o…

RT @mlazqui: Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/TaWZisvkzA

RT @mlazqui: Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/TaWZisvkzA

RT @mlazqui: Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/TaWZisvkzA

RT @DrAndrewLoblaw: Ian Tannock Prof Emeritus and GU God just gave rounds @Sunnybrook arguing exactly the same point. RCTs should have OS o…

RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…

RT @mlazqui: Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/TaWZisvkzA

RT @fpesty: Nous savions déjà que la survie sans progression, critère indirecte de jugement en oncologie, n’était pas corrélée à l’améliora…

RT @chadinabhan: This @JAMAInternalMed paper on lack of correlation between PFS and HRQOL should give all a pause into which points are cri…

RT @chadinabhan: This @JAMAInternalMed paper on lack of correlation between PFS and HRQOL should give all a pause into which points are cri…

RT @chadinabhan: This @JAMAInternalMed paper on lack of correlation between PFS and HRQOL should give all a pause into which points are cri…

RT @chadinabhan: This @JAMAInternalMed paper on lack of correlation between PFS and HRQOL should give all a pause into which points are cri…

It should not. 🔺We made this very clear in our @jco article early this year: 🔺https://t.co/rLx36XCHS1 🔺With the caveat of Ian Tannock’s data w survival post-progression <1 year, PFS probably is reasonable OS surrogate (if no high fatal toxicities) 🔺htt

RT @chadinabhan: This @JAMAInternalMed paper on lack of correlation between PFS and HRQOL should give all a pause into which points are cri…

RT @TheWonkologist: If what we value is survival and quality of life, then why not measure survival and quality of life rather than PFS? In…

Increasingly, the need to monitor, measure of treatment interventions on their impact on patient QoL is becoming more critical. In Oncology Clinical Trials, this paper failed to see significant associations between PFS and HRQoL, w…https://t.co/uEAsWQEzTi

RT @geri_doc: Progression-Free Survival (PFS) is a very common outcome measure in Oncology Important analysis shows little relationship to…

RT @TheWonkologist: If what we value is survival and quality of life, then why not measure survival and quality of life rather than PFS? In…

RT @AshleyHenkel: Study in @JAMAInternalMed failed to find significant association between progression-free survival & quality of life in c…

RT @TheWonkologist: If what we value is survival and quality of life, then why not measure survival and quality of life rather than PFS? In…

RT @fpesty: Nous savions déjà que la survie sans progression, critère indirecte de jugement en oncologie, n’était pas corrélée à l’améliora…

RT @dhjutsw1: ICYMI: Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology. @UTSWIMchief @UTSWIMJ…

RT @f_g_zampieri: This is a must read. Kudo's to the authors for a terrific and necessary paper. PFS is a misleading endpoint that means li…

RT @rajshekharucms: Important meta-analysis questioning the dogma that PFS is a surrogate of #HRQoL; A key example is PALOMA-2 where >10 mo…

If what we value is survival and quality of life, then why not measure survival and quality of life rather than PFS? Interesting, important work on the PFS outcome in @JAMAInternalMed https://t.co/YobGyU66Om

Study in @JAMAInternalMed failed to find significant association between progression-free survival & quality of life in cancer clinical trials. Raises questions regarding assumption that interventions prolonging PFS also improve HRQoL in patients. http

RT @mlazqui: Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/TaWZisvkzA

RT @Januleras: No existe asociación entre Supervivencia Libre de Progresión y Calidad de Vida Relacionada con la Salud en pacientes oncológ…

RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…

RT @AndersPerner: Involve the patients - the use of surrogate markers in trials and drug development may not improve patient care https://t…

Ian Tannock Prof Emeritus and GU God just gave rounds @Sunnybrook arguing exactly the same point. RCTs should have OS or QOL advantage as primary outcome (or have proven surrogates for that outcome). These R important data against PFS as a QOL surrogate.

No existe asociación entre Supervivencia Libre de Progresión y Calidad de Vida Relacionada con la Salud en pacientes oncológicos. Qué contrariedad...

RT @sarojniraula: Message from this study is worth pondering up on much more than that of most individual RCTs https://t.co/3k5yJOyzir

RT @mlazqui: Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/TaWZisvkzA

RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…

RT @geri_doc: Progression-Free Survival (PFS) is a very common outcome measure in Oncology Important analysis shows little relationship to…

RT @chadinabhan: This @JAMAInternalMed paper on lack of correlation between PFS and HRQOL should give all a pause into which points are cri…

Another sane voice.. PFS not a valid surrogate marker for QOL.. let's talk of either OS or QOL @ESSOnews @VPplenarysesh @oncology_bg Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/z5OcCYeVVl

Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/TaWZisvkzA

Still mystified by the elevation of HRQoL to a hard outcome. OK, PFS is a bad surrogate for a surrogate. But so what?

Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/KMfoO70f0G

Important. Il est amusant (?) que l'@INCa_veillePro soit aussi peu promotrice de ce genre d'articles... Mais j'ai dû mal lire...

Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/P47DVuNAsi Otra creencia q se nos cae. Los pacientes q viven más sin progresión de su cáncer metastásico no disfrutan de mejor calidad de vida

RT @rajshekharucms: Important meta-analysis questioning the dogma that PFS is a surrogate of #HRQoL; A key example is PALOMA-2 where >10 mo…